Japanese pharma company wins arbitration over cancer drug

16-08-2022

Staff Writer

Japanese pharma company wins arbitration over cancer drug

Postmodern Studio / Shutterstock.com

Dispute over the Enhertu (Trastuzumab deruxtecan) began in 2019 | Antibody drug conjugate tech at issue | American Arbitration Association issued final decision.


Daiichi Sankyo, Seagen, breast cancer, patent infringement, biopharmaceutical, arbitration, Enhertu

LSIPR